Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9116547 | 0.73 | MEN1 (0.52) | MEN1ALDH1A1TP53CYP3A4MAPT | |
| SCHEMBL57168 | 0.73 | ALDH1A1 (0.47) | MEN1ALDH1A1TP53CYP3A4MAPT | |
| SCHEMBL3530070 | 0.67 | KDM4E (0.42) | MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL25311012 | 0.62 | MEN1 (0.39) | MEN1ALDH1A1TP53CYP3A4MAPT | |
| SCHEMBL3522460 | 0.62 | — | — | |
| SCHEMBL9115923 | 0.62 | MEN1 (0.46) | MEN1ALDH1A1TP53CYP3A4MAPT | |
| SCHEMBL15902224 | 0.58 | — | — | |
| SCHEMBL23522361 | 0.57 | MEN1 (0.35) | MEN1ALDH1A1TP53CYP3A4MAPT | |
| SCHEMBL21018280 | 0.57 | MEN1 (0.35) | MEN1ALDH1A1TP53CYP3A4MAPT | |
| SCHEMBL21896579 | 0.57 | MAPK1 (0.38) | MEN1ALDH1A1TP53CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111825660-A | Compound, thermal activation delayed fluorescence material, organic electroluminescent device and application | 北京鼎材科技有限公司 | 2020-10-27 | — | — | CN | claimed |
| CN-112103395-B | Organic electroluminescent device and electronic apparatus | 陕西莱特光电材料股份有限公司 | 2022-11-15 | — | — | CN | disclosed |
| CN-112103395-A | Organic electroluminescent device and electronic apparatus | 陕西莱特光电材料股份有限公司 | 2020-12-18 | — | — | CN | disclosed |
| CN-111825660-A | Compound, thermal activation delayed fluorescence material, organic electroluminescent device and application | 北京鼎材科技有限公司 | 2020-10-27 | — | — | CN | disclosed |
| CN-102438452-B | Compounds and compositions comprising CDK inhibitors and methods for treating cancer | UNIV GEORGIA STATE RES FOUND | 2015-02-25 | — | — | CN | disclosed |
| US-20120121692-A1 | COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR TREATING CANCER | SHANDONG UNIVERSITY (CN) | 2012-05-17 | — | — | US | disclosed |
| CN-102438452-A | Compounds and compositions comprising cdk inhibitors and methods for the treatment of cancer | UNIV GEORGIA STATE RES FOUND | 2012-05-02 | — | — | CN | disclosed |
| EP-2429292-A1 | COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR THE TREATMENT OF CANCER | Georgia State University Research Foundation, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010129858-A1 | COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR THE TREATMENT OF CANCER | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121692-A1 | COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR TREATING CANCER | CDK6, CDK5, CDK4 | MEN1 2944/4885ALDH1A1 2643/4885TP53 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.